Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Fleming on the Rationale of the SPOTLIGHT Trial in Prostate Cancer

May 13th 2022

Mark T. Fleming, MD, discusses the rationale and results from the phase 3 SPOTLIGHT trial in prostate cancer.

Emerging Targeted Therapies in mCRPC

May 12th 2022

Before closing out their discussion, experts review novel targeted agents under investigation in metastatic CRPC.

Defining Unmet Needs in the Management of mCRPC

May 12th 2022

Experts share insight on the greatest unmet needs in treating patients with metastatic castration-resistant prostate cancer.

Selecting Among Novel Imaging Options in Metastatic CRPC

May 11th 2022

A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.

Metastatic CRPC: Utility of Imaging as a Biomarker

May 11th 2022

Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.

Novartis Suspends Production of Radioligand Therapy Agents in New Jersey and Italy

May 9th 2022

Pharmaceutical giant Novartis has temporarily halted radioligand therapy production at sites in Millburn, New Jersey, and Ivrea, Italy, citing potential quality issues in its manufacturing processes.

Niraparib Improves or Maintains HRQOL in Metastatic Castration-Resistant Prostate Cancer

May 7th 2022

Niraparib was found to maintain or improve health-related quality of life in patients with advanced or metastatic castration-resistant prostate cancer, according to data from the final analysis of the phase 2 GALAHAD trial.

Ongoing PSMA-Targeted Radioligand Trials in mCRPC

May 5th 2022

Andrew J. Armstrong, MD, MSc, breaks down ongoing prostate cancer clinical trials looking at targeted radioligand therapies.

Metastatic CRPC: Considerations for Radiotherapy

May 5th 2022

Oliver Sartor, MD, considers the respective roles of Lu-PSMA-617 and radium-223 as radiotherapy in the setting of mCRPC.

DNA Alterations and Selection of PARP Inhibitors in mCRPC

May 4th 2022

Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.

Overview of Therapy for mCRPC: PARP Inhibitors

May 4th 2022

A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.

Addition of Apalutamide to ADT Does Not Reduce HRQOL in Metastatic Castration-Sensitive Prostate Cancer

May 3rd 2022

The addition of apalutamide to androgen deprivation therapy was not found to significantly reduce health-related quality of life or increase patient-reported adverse effect burden in patients with metastatic castration-sensitive prostate cancer enrolled to the phased 3 TITAN trial.

FDA Grants Priority Review to Darolutamide/Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

May 3rd 2022

The FDA has accepted a supplemental new drug application and granted priority review to darolutamide plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Armstrong Highlights Outcomes of Final Survival Analysis of Enzalutamide Plus ADT in mHSPC

May 2nd 2022

Andrew J. Armstrong, MD, discusses the updated results and the clinical implications of the final survival analysis of the ARCHES trial, which he coauthored.

Enzalutamide Plus ADT Demonstrates Significant Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer

April 28th 2022

Treatment with the androgen-receptor inhibitor enzalutamide plus androgen deprivation therapy led to significant survival benefits in patients with metastatic hormone-sensitive prostate cancer.

Potential Role of Lu-PSMA-617 in mCRPC

April 28th 2022

Expert perspectives on where Lu-PSMA-617 therapy may fit into the treatment paradigm for metastatic castration-resistant prostate cancer.

VISION Trial: Lu-PSMA-617 in mCRPC

April 28th 2022

A comprehensive review of the design and results of VISION, which analyzed Lu-PSMA-617 therapy in patients with mCRPC.

Interpreting Data From the ARASENS Trial in Metastatic HSPC

April 27th 2022

Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.

Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial

April 27th 2022

Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.

Dr. Armstrong on Updated Results of the ARCHES Trial in mHSPC

April 26th 2022

Andrew J. Armstrong, MD, MSc, discusses updated results from the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.